Cyclerion Therapeutics Inc.
13F holders, Q1 2025 (March 31)18holders −1
0new positions
1sold out
$2.50avg. 13F price*
At the end of Q1 2025, 18 institutions reported holding Cyclerion Therapeutics Inc. in their 13F filings, down 1 from Q4 2024. 0 opened new positions and 1 sold out. The largest holders were Tyndall Capital Partners L P ($412K), Siren, L.L.C. ($290K) and Geode Capital Management, LLC ($78K).
- Company
- Cyclerion Therapeutics Inc.
- CUSIP
- 23255M204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $34K |
All 13F filers, Q4 2024 → Q1 2025: 3,534 shares bought and 12,215 shares sold, net −8,681 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Tyndall Capital Partners L P | 100.00% | No change | 164,777 | $412K |
| Siren, L.L.C. | 0.02% | No change | 116,155 | $290K |
| Geode Capital Management, LLC | 0.00% | Reduce -0.7% | 31,603 | $78K |
| Vanguard Group Inc. | 0.00% | No change | 23,490 | $58K |
| BlackRock, Inc. | 0.00% | No change | 16,797 | $42K |
| UBS Group AG | 0.00% | Add +34.5% | 13,001 | $33K |
| FMR LLC | 0.00% | Add +4.2% | 4,940 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -56.8% | 1,054 | $3K |
| Morgan Stanley | 0.00% | No change | 649 | $2K |
| Group One Trading LLC | 0.00% | No change | 540 | $1K |
| Osaic Holdings, Inc. | 0.00% | No change | 130 | $325 |
| Activest Wealth Management | 0.00% | No change | 100 | $250 |
| MAI Capital Management | 0.00% | No change | 100 | $250 |
| Elevation Wealth Partners, LLC | 0.00% | No change | 20 | $50 |
| Bank of America Corp. | 0.00% | No change | 19 | $48 |
| SBI Securities Co., Ltd. | 0.00% | No change | 11 | $28 |
| BNP Paribas Financial Markets | 0.00% | No change | 5 | $12 |
| Northwestern Mutual Wealth Management Co. | 0.00% | No change | 1 | $3 |
"% of holder's portfolio" is CYCLERION THERAPEUTICS INC's weight in each manager's 13F, not the share of Cyclerion Therapeutics Inc. the manager owns.